A multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alport's syndrome

Oliver Gross, Burkhard Tönshoff, Lutz T. Weber, Lars Pape, Kay Latta, Henry Fehrenbach, Baerbel Lange-Sperandio, Hildegard Zappel, Peter Hoyer, Hagen Staude, Sabine König, Ulrike John, Jutta Gellermann, Bernd Hoppe, Matthias Galiano, Britta Hoecker, Rasmus Ehren, Christian Lerch, Clifford E. Kashtan, Markus HardenJan Boeckhaus, Tim Friede, Michael Koziolek, Carsten Paul Bramlage, Frauke Weber, Tanja Albrecht-Nock, Joseph Sonntag, Jenny Frese, Matthias Kettwig, Reinhard Hilgers, Matthias Hansen, Mirja Wedekin, Nicole Meyer, Susanne Klaiber, Michaela Gessner, Max Liebau, Anne Kristin Vogt-Weigeldt, Therese Jungraithmayr, Sabine Ponsel, Ulrike Jacoby, Martin Konrad, Brigitta Kranz, Jens Koenig, Lisa Loechtermann, Michael Pohl, Ralf Husain, Katrin Mueller, Julia Thumfart, Gesa Schalk, Markus Feldkoetter, Sabine Schmidt, Katja Sauerstein, Evelin Muschiol, Heiko Billing, Frauke Wilkening

Research output: Contribution to journal › Article › peer-review

89 Scopus citations

Fingerprint

Dive into the research topics of 'A multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alport's syndrome'. Together they form a unique fingerprint.

Medicine & Life Sciences